ReviewInflammopharmacology2025
Polyphenolic protection: the role of mangiferin in mitigating neurodegeneration and neuroinflammation.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Potential Relevance of Amazonian Diet Components in Parkinson's Disease: An Integrative Review with Multivariate Analysis.Nutrients · 2026Review
- Disease mechanisms and translational barriers guide nanocarrier design for nose to brain delivery in Alzheimer's disease.Discover nano · 2026Review
- Cognitive and Mood Effects of a Soluble Mango Leaf Extract (ZynamitePharmaceuticals (Basel, Switzerland) · 2026Article
- Alterations in glutamatergic and GABAergic signaling in ketamine-induced neurotoxicity: mangiferin mitigates neurochemical, oxidative, and astrocytic dysregulation in the rat temporal-frontal cortex.Behavioral and brain functions : BBF · 2026Article
- Phytochemical Characterization and Immunometabolic Modulation byInternational journal of molecular sciences · 2026Article
- Polyphenol-based modulation of the Glo1-Nrf2-RAGE axis in diabetes and neurodegeneration: mechanistic evidence, translational constraints, and critical appraisal.Frontiers in pharmacology · 2026Review
- Mangiferin Mitigates Ketamine-Induced Dopaminergic and Glial Dysregulation and Modulates Nrf2 Expression in a Rat Schizophrenia-Like Model.Journal of experimental pharmacology · 2026Article
- Review
- Therapeutic potential of purpurin, a natural anthraquinone dye, in neuroprotection and neurological disorders.Inflammopharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mangiferin, a polyphenol of natural occurrence predominantly present in Mangifera indica, has attracted significant interest because of its multiplicity of pharmacological activities, of which its neuroprotective activity is of particular interest. Herein, the review delves into the biosynthetic mechanisms, structural properties, and action mechanisms responsible for the therapeutic value of mangiferin in neurological disorders. Of special note is that mangiferin has antioxidative, anti-inflammatory, and anti-apoptotic activities, which are responsible for its effectiveness in reducing cognitive impairments and neuronal damage in disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, epilepsy, depression, anxiety, and general cognitive decline. Though being of low bioavailability, more recent approaches such as chemical derivatization, nanoparticle-mediated drug delivery, and intranasal delivery have the promise to enhance its central nervous system (CNS) delivery. By combining preclinical and mechanistic studies, the review herein highlights the potential of mangiferin as a multitherapeutic neuroprotectant and addresses new approaches to facilitate its clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.